A carregar...
4CPS-170 Evaluation of zoledronic acid in the treatment of bone diseases with high risk of fractures
BACKGROUND: Zoledronic acid (ZOL) administered as a 5 mg intravenous infusion anually is indicated for the treatment of bone diseases such as Paget disease and osteoporosis with a high risk of fracture. It is strongly advised that patients treated with ZOL receive adequate calcium and vitamin D (cal...
Na minha lista:
| Publicado no: | Eur J Hosp Pharm |
|---|---|
| Main Authors: | , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
BMJ Group
2018
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7535356/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/ejhpharm-2018-eahpconf.260 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|